Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Results of IDEC-151/SB-217969 phase I trial reported

Dec. 4, 1997

S-2474: antiarthritic agent with dual NSAID/DMARD profile

Dec. 4, 1997

Amarillo reports positive phase II data in Sjogren's syndrome trial

Dec. 3, 1997

Almirall discloses new COX-2-selective compounds

Dec. 2, 1997

Teva receives FDA approval for generic etodolac

Dec. 1, 1997

JT licenses new oral antiinflammatory agent to R.W. Johnson

Nov. 26, 1997

Anika signs Orthovisc marketing agreement with Zimmer

Nov. 25, 1997

InKine (formerly Panax) completes acquisitions, raises funds for CBP-1011 development

Nov. 21, 1997

Collagenase treatment for Dupuytren's disease enters phase II

Nov. 21, 1997

Phase II results with T-cell receptor peptides in RA promising

Nov. 20, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...